scholarly journals Desulfurization of Automotive Fuels by the Adsorption Method Using Adsorbents of Natural Origin

2021 ◽  
Vol 666 (5) ◽  
pp. 052044
Author(s):  
K V Bryankin ◽  
Ehsan Hashim Mohammed Alaameri ◽  
N N Balobaeva
1986 ◽  
Vol 55 (02) ◽  
pp. 271-275 ◽  
Author(s):  
Helen Ireland ◽  
D A Lane ◽  
Angela Flynn ◽  
E Anastassiades ◽  
J R Curtis

SummaryThe heparinoid of natural origin Org 10172 has anti-factor Xa activity but minimal anti-thrombin activity, and little effect upon broad spectrum assays such as the KCCT in vitro. Its anticoagulant effects have been compared to those of commercial heparin in 7 patients undergoing haemodialysis for chronic renal failure. Commercial heparin was administered in a dose (5,000 iu bolus + 1,500 iu/hour continuous iv infusion) previously shown to inhibit fibrin formation during haemodialysis. This produced mean anti-factor Xa levels in plasma between 0.7-1.0 iu/ml and largely suppressed fibrin formation for 5 h dialysis measured as mean FPA levels in plasma. Administration of Org 10172 as a bolus of 1,350 anti-factor Xa u or 2,000-2,400 anti-factor Xa u produced plasma anti-factor Xa levels of less than 0.5 u/ml and allowed fibrin clot and FPA generation during dialysis. Org 10172 administered as a bolus dose of 4,000-4,800 anti-factor Xa u produced mean anti-factor Xa levels of greater than 0.5 u/ml, allowed dialysis of 6 patients for 5 h and appreciably suppressed FPA generation during dialysis, with little effect on the KCCT.It is concluded that the anti-factor Xa activity of Org 10172 may reflect its ability to inhibit fibrin during dialysis and that single bolus injection of Org 10172 may be a useful alternative method of achieving anticoagulation.


2016 ◽  
Vol 136 (4) ◽  
pp. 186-192 ◽  
Author(s):  
Shohei Use ◽  
Yoshinobu Murakami ◽  
Hiroyuki Muto ◽  
Tomohiro Kawashima ◽  
Masayuki Nagao

1974 ◽  
Author(s):  
S. Koncar-Djurdjevic ◽  
M. Mitrovic ◽  
S. Cvijovic ◽  
G. Popovic ◽  
Dimitrije Voronjec

Author(s):  
O. L. Zolotukhina ◽  
◽  
Ju. G. Romanova ◽  
O. V. Maslov ◽  
◽  
...  

Diseases of periodontal tissues occupy one of the leading positions among modern dental problems, namely the multifactorial nature of these diseases. In modern dental science, the issue of the development of periodontal pathology against the background of somatic pathology and risk factors remains relevant. Pathology of periodontal tissues in 68–90 % of cases is accompanied by chronic diseases of the gastrointestinal tract. Today, there is no doubt that Helicobacter pylori infection can be present in the biotopes of the oral cavity and can affect the course of periodontal pathology. As you know, smoking is one of the important risk factors for the development of inflammatory-dystrophic diseases of periodontal tissues, which can aggravate the course of the latter. The purpose of the work is to determine the prevalence of oral Helicobacter pylori infection in tobacco-dependent patients with chronic generalized periodontitis on the background of chronic hyperacid gastritis during treatment. Patients who received the proposed therapeutic and prophylactic complex (ultraphonophoresis procedures with the created gel «Apisan», and probiotic drug BioGaia ProDentis and angioprotective drug of natural origin — Detralex) showed a gradual decrease in the level of total urease activity and, as a consequence, a decrease the prevalence of Helicobacter pylori infection in the oral cavity according to the results of a urease rapid test with material from the oral cavity, both in the presence of a risk factor — smoking, and in its absence. The use of the proposed therapeutic and prophylactic complex proved to be effective in reducing the prevalence of oral Helicobacter pylori infection in smoking patients and patients who do not smoke, with chronic generalized periodontitis against the background of chronic hyperacidal gastritis associated with Helicobacter pylori.


Sign in / Sign up

Export Citation Format

Share Document